> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 2 Octagam Lots Withdrawn from Market
- URL: https://www.fdaweb.com/2-octagam-lots-withdrawn-from-market/
- Published: 2017-10-23T12:00:00.000Z
- Updated: 2026-09-14T22:57:29.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5139935

Octapharma USA has decided to withdrawal two lots of Octagam 10% \[immune globulin intravenous (human)\] liquid preparation\] that is labeled with lot numbers K724B8541 and K725A8541\. “Although there have been no reports of serious injury at this time,” an FDA online [notice](https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm581080.htm?ref=fdaweb.com) says, “Octapharma has determined through consultation with the public health authorities at FDA, the most prudent course of action is to suspend further administration of octagam 10% from these particular production lots.” The agency notice does not contain any explanation of the cause for the market withdrawal.